Insider Selling: Labcorp (NYSE:LH) EVP Sells 234 Shares

Labcorp Holdings Inc. (NYSE:LH) EVP Bryan Vaughn sold 234 shares of the firm’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $286.19, for a total value of $66,968.46. Following the completion of the sale, the executive vice president directly owned 6,746 shares in the company, valued at approximately $1,930,637.74. The trade was a 3.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Labcorp Price Performance

Shares of LH stock traded down $3.64 during trading hours on Monday, hitting $283.34. 56,019 shares of the company’s stock were exchanged, compared to its average volume of 671,858. The company has a quick ratio of 1.54, a current ratio of 1.73 and a debt-to-equity ratio of 0.68. The firm has a market cap of $23.23 billion, a P/E ratio of 25.10, a P/E/G ratio of 2.01 and a beta of 0.89. The firm has a 50 day moving average of $262.24 and a two-hundred day moving average of $266.27. Labcorp Holdings Inc. has a fifty-two week low of $241.81 and a fifty-two week high of $293.72.

Labcorp (NYSE:LH) last released its quarterly earnings results on Thursday, April 30th. The medical research company reported $4.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.09 by $0.16. Labcorp had a net margin of 6.66% and a return on equity of 16.29%. The firm had revenue of $3.54 billion for the quarter, compared to analysts’ expectations of $3.51 billion. During the same quarter last year, the company earned $3.84 EPS. The firm’s revenue for the quarter was up 5.8% compared to the same quarter last year. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. Sell-side analysts forecast that Labcorp Holdings Inc. will post 18 EPS for the current year.

Labcorp Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, June 11th. Shareholders of record on Friday, May 29th were issued a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 1.0%. The ex-dividend date of this dividend was Friday, May 29th. Labcorp’s dividend payout ratio (DPR) is presently 25.51%.

Institutional Trading of Labcorp

Several hedge funds have recently made changes to their positions in the company. JPL Wealth Management LLC purchased a new stake in shares of Labcorp during the 3rd quarter valued at approximately $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in Labcorp during the fourth quarter worth $26,000. Hilton Head Capital Partners LLC acquired a new stake in Labcorp during the fourth quarter worth $27,000. Eagle Bay Advisors LLC purchased a new stake in Labcorp in the fourth quarter valued at $29,000. Finally, DV Equities LLC purchased a new stake in Labcorp in the fourth quarter valued at $29,000. Hedge funds and other institutional investors own 95.94% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently commented on LH shares. Evercore reissued an “outperform” rating and set a $300.00 target price on shares of Labcorp in a research note on Wednesday, April 8th. Wall Street Zen cut Labcorp from a “buy” rating to a “hold” rating in a report on Saturday, June 13th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Labcorp in a research note on Friday, May 8th. Finally, Robert W. Baird set a $334.00 target price on Labcorp in a report on Friday, May 1st. Eight research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $308.00.

About Labcorp

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.